MicroRNA‑30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9 Retraction in /10.3892/ol.2024.14232

Jiang,Lining; Liu,Yabin; Ma,Can; Li,Binghui

doi:10.3892/ol.2018.8999

MicroRNA‑30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9

Retraction in: /10.3892/ol.2024.14232

Authors:
- Lining Jiang
- Yabin Liu
- Can Ma
- Binghui Li
View Affiliations

Affiliations: Department of Urology, Cangzhou Central Hospital, Cangzhou, Hebei 061110, P.R. China, Department of Urology, Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei 050011, P.R. China, Department of Oncology, Shijiazhuang City No. 1 People's Hospital, Shijiazhuang, Hebei 050011, P.R. China
Published online on: June 20, 2018 https://doi.org/10.3892/ol.2018.8999
Pages: 3038-3044
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing number of studies reported that microRNA (miR)‑30a was dysregulated in several types of human cancer and may contribute to cancer carcinogenesis and progression. However, its expression and roles in renal cell carcinoma (RCC) remain unknown. In the present study, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to quantify miR‑30a expression in RCC tissues and cell lines. The cell counting kit‑8 assay, migration and invasion assays were used to evaluate the roles of miR‑30a on the proliferation, migration and invasion of RCC cells. The target gene of miR‑30a was identified by luciferase reporter assays, RT‑qPCR and western blotting. The results indicated that miR‑30a was downregulated in RCC tissues and cell lines compared with corresponding noncancerous tissues and normal renal cell line, respectively. Re‑expression of miR‑30a inhibited the proliferation, migration and invasion of RCC cells. Additionally, ADAM metallopeptidase domain 9 (ADAM9) was validated as a direct target of miR‑30a. Furthermore, the knockdown of ADAM9 by small interfering RNAs was able to mimic the effects of miR‑30a overexpression in RCC cells. These results highlight the important role for miR‑30a in the occurrence and development of RCC, and the restoration of miR‑30a might be investigated as a potential strategy for treating RCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
3	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010. View Article : Google Scholar : PubMed/NCBI
4	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
5	Decastro GJ and McKiernan JM: Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am. 35(581–592): vi2008.
6	Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF and Sinescu IC: European Association of Urology Guideline Group: EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol. 58:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
7	Park I, Lee JL, Ahn JH, Lee DH, Lee KH, Jeong IG, Song C, Hong B, Hong JH and Ahn H: Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol. 140:1421–1428. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hirata H, Hinoda Y, Ueno K, Nakajima K, Ishii N and Dahiya R: MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis. 33:501–508. 2012. View Article : Google Scholar : PubMed/NCBI
10	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
11	de Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: A review. Anal Chim Acta. 699:134–152. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ha TY: MicroRNAs in human diseases: From cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011. View Article : Google Scholar : PubMed/NCBI
14	Tang Y, Wan W, Wang L, Ji S and Zhang J: microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma. Int J Clin Exp Pathol. 8:15611–15621. 2015.PubMed/NCBI
15	Shi Q, Xu X, Liu Q, Luo F, Shi J and He X: MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma. Oncol Lett. 11:1474–1480. 2016. View Article : Google Scholar : PubMed/NCBI
16	Gao Y, Ma X, Yao Y, Li H, Fan Y, Zhang Y, Zhao C, Wang L, Ma M, Lei Z and Zhang X: miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2. Oncotarget. 7:20324–20337. 2016.PubMed/NCBI
17	Li Y, Chen D, Jin LU, Liu J, Li Y, Su Z, Qi Z, Shi M, Jiang Z, Yang S, et al: Oncogenic microRNA-142-3p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Oncol Lett. 11:1235–1241. 2016. View Article : Google Scholar : PubMed/NCBI
18	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G and Yang Q: MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene. 33:3119–3128. 2014. View Article : Google Scholar : PubMed/NCBI
20	Tang R, Liang L, Luo D, Feng Z, Huang Q, He R, Gan T, Yang L and Chen G: Downregulation of MiR-30a is associated with poor prognosis in lung cancer. Med Sci Monit. 21:2514–2520. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang C, Ma X, Du J, Yao Z, Shi T, Ai Q, Chen X, Zhang Z, Zhang X and Yao X: MicroRNA-30a as a prognostic factor in urothelial carcinoma of bladder inhibits cellular malignancy by antagonising Notch1. BJU Int. 118:578–589. 2016. View Article : Google Scholar : PubMed/NCBI
22	Li WF, Dai H, Ou Q, Zuo GQ and Liu CA: Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway. Tumour Biol. 37:5885–5895. 2016. View Article : Google Scholar : PubMed/NCBI
23	Liu Z, Chen L, Zhang X, Xu X, Xing H, Zhang Y, Li W, Yu H, Zeng J and Jia J: RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells. J Cell Mol Med. 18:610–623. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zhong M, Bian Z and Wu Z: miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem. 31:209–218. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao J, Wang Y, Yang S and Pu P: Analysis of hsa-miR-30a-5p expression in human gliomas. Pathol Oncol Res. 19:405–411. 2013. View Article : Google Scholar : PubMed/NCBI
26	Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL and Shen CY: MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat. 134:1081–1093. 2012. View Article : Google Scholar : PubMed/NCBI
27	Wen XP, Ma HL, Zhao LY, Zhang W and Dang CX: MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. Cell Mol Biol (Noisy-le-grand). 61:78–85. 2015.PubMed/NCBI
28	Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran P, Sun L, Huang Q, Xie F, Du J and Xiao C: Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2. Acta Biochim Biophys Sin (Shanghai). 48:220–228. 2016. View Article : Google Scholar : PubMed/NCBI
29	Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
30	Wang Z, Dai X, Chen Y, Sun C, Zhu Q, Zhao H, Liu G, Huang Q and Lan Q: MiR-30a-5p is induced by Wnt/β-catenin pathway and promotes glioma cell invasion by repressing NCAM. Biochem Biophys Res Commun. 465:374–380. 2015. View Article : Google Scholar : PubMed/NCBI
31	Jia Z, Wang K, Wang G, Zhang A and Pu P: MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS One. 8:e550082013. View Article : Google Scholar : PubMed/NCBI
32	Wang HY, Li YY, Fu S, Wang XP, Huang MY, Zhang X, Shao Q, Deng L, Zeng MS, Zeng YX and Shao JY: MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Exp Biol Med (Maywood). 239:891–898. 2014. View Article : Google Scholar : PubMed/NCBI
33	Xiong J, Wei B, Ye Q and Liu W: MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration. Biochem Biophys Res Commun. 18–Mar;2016.(Epub ahead of print). View Article : Google Scholar
34	Chang CW, Yu JC, Hsieh YH, Yao CC, Chao JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY and Cheng CW: MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer. Oncotarget. 7:16462–16478. 2016.PubMed/NCBI
35	Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G and Bagnato A: miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 7:4009–4023. 2016. View Article : Google Scholar : PubMed/NCBI
36	Jiang D, Zheng X, Shan W and Shan Y: The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2. Tumour Biol. 37:5933–5940. 2016. View Article : Google Scholar : PubMed/NCBI
37	Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA and Blobel CP: ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol. 29:2694–2703. 2009. View Article : Google Scholar : PubMed/NCBI
38	Duffy MJ, McKiernan E, O'Donovan N and McGowan PM: Role of ADAMs in cancer formation and progression. Clin Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
39	Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and Kristiansen G: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 8:1792008. View Article : Google Scholar : PubMed/NCBI
40	Wang S, Wang X, Guo Q, Wang G, Han X, Li X, Shi ZW and He W: MicroRNA-126 overexpression inhibits proliferation and invasion in osteosarcoma cells. Technol Cancer Res Treat. 15:NP49–NP59. 2016. View Article : Google Scholar : PubMed/NCBI
41	Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M and Yuan Q: microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett. 585:1828–1834. 2011. View Article : Google Scholar : PubMed/NCBI